The herpangina treatment market size has grown strongly in recent years. It will grow from $1.86 billion in 2024 to $1.98 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to viral outbreaks and prevalence, pediatric population growth, healthcare infrastructure development, public health awareness programs, clinical research and treatment advancements.
The herpangina treatment market size is expected to see strong growth in the next few years. It will grow to $2.68 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to emerging viral strains, increasing focus on pediatric health, international health regulations, technological innovations in diagnostics, healthcare access improvements. Major trends in the forecast period include development of topical therapies for oral lesions, integration of telemedicine for diagnosis and consultation, enhanced patient education and awareness programs, collaborations for clinical trials and research, global health preparedness initiatives.
The growth of the herpangina treatment market is anticipated to be driven by an increase in research and development activities. Herpangina is a viral infection that primarily affects children, leading to painful sores or ulcers in the throat and tonsils, typically caused by coxsackievirus and enteroviruses. Treatments for herpangina aim to alleviate symptoms such as blisters, high fever, mouth or throat discomfort, drooling, and loss of appetite. For instance, in April 2024, the Office for National Statistics, a UK-based national statistical agency, reported that the UK government’s net expenditure on research and development increased by 10.5% in 2022, amounting to £15.5 billion ($19.5 billion), compared to £14 billion ($17.7 billion) in 2021. Thus, the rise in research and development activities is contributing to the growth of the herpangina treatment market.
The growth of the herpangina treatment market is also expected to be fueled by the increasing pediatric population. This population segment, encompassing individuals from birth to adolescence or maturity, requires specific attention in herpangina treatment, focusing on symptom management, supportive care, and ensuring proper hydration. The Federal Interagency Forum on Child and Family Statistics reported around 72.5 million children in the United States in 2022, with a projected increase to 78.2 million by 2050. This rise in the pediatric population is a significant driver for the growth of the herpangina treatment market.
The growth of the herpangina treatment market is expected to be propelled by a surge in healthcare expenditure. Healthcare expenditure encompasses all costs related to health services, nutrition activities, family planning, and emergency aid designated for health. An increase in healthcare spending can contribute to the expansion of resources and the availability of trained healthcare professionals for herpangina treatment. According to the Centers for Medicare & Medicaid Services, the National Health Expenditure (NHE) increased by 2.7% to $4.3 trillion in 2021, reaching $12,914 per person. Projected annual increases of 5.1 percent and a 19.6 percent share of GDP in 2030 indicate sustained growth in healthcare expenditure, driving the herpangina treatment market.
The development of treatments for herpangina-related diseases, such as aphthous stomatitis, is a notable trend gaining traction in the herpangina treatment market. Major companies in the market are actively working on therapies to alleviate pain in individuals with recurrent mouth ulcers. For instance, in September 2022, Mucocort, a Sweden-based healthcare company, partnered with Aurena Laboratories AB to create a unique self-absorbing pain relief patch for individuals suffering from recurrent mouth ulcers and aphthous stomatitis, facilitating pain relief and accelerating the natural healing process.
Key players in the herpangina treatment market are focusing on the development of new treatments, including Acetaminophen pain relief products for adults. These products, containing acetaminophen as the active ingredient, aim to relieve pain and reduce fever. In April 2022, Genexa, a US-based pharmaceutical company, introduced 'Genexa Acetaminophen Extra Strength' and 'Acetaminophen PM caplets' for temporary relief from minor aches, discomfort associated with conditions such as the common cold, headaches, backaches, arthritis pain, toothaches, muscular aches, and premenstrual and menstrual cramps. The launch of such products contributes to the diversification and growth of the herpangina treatment market.
Major companies operating in the herpangina treatment market include Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Limited, Pfizer Inc, AstraZeneca, Novartis AG, GlaxoSmithKline Plc, Merck & Co., Inc., AbbVie Inc., Eli Lilly and Company, Bayer AG, Sanofi, Bristol-Myers Squibb Company, Johnson & Johnson, Mucocort, Aurena Laboratories AB, Cipla Inc., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Zydus Cadila, Aurobindo Pharma Ltd., Lupin Limited, Glenmark Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., F. Hoffmann-La Roche AG, Boehringer Ingelheim International GmbH, Sandoz International GmbH, Endo International plc, Mylan N.V., CSL Limited.
North America was the largest region in the global herpangina treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the herpangina treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the herpangina treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Herpangina treatment involves managing the symptoms of the viral illness that commonly affects children, causing painful sores or ulcers on the tonsils and the back of the throat. Treatment focuses on alleviating symptoms and supporting the body's natural healing process, as herpangina is a viral infection that typically resolves on its own without the need for specific antiviral medications.
The main types of herpangina treatment include topical anesthetics, ibuprofen or acetaminophen, and others. Topical anesthetics are a form of local anesthesia applied to the skin's surface or mucous membrane to temporarily numb the affected region. Herpangina is caused by viruses such as coxsackie virus A, coxsackie virus B, enterovirus 71, and echovirus, leading to various symptoms such as high fever, sore throat, blisters or ulcers in the throat and mouth, difficulty swallowing, loss of appetite, headache, neck pain, and swollen lymph glands. These treatments are utilized by various end-users, including hospitals, home care settings, specialty clinics, and others.
The herpangina treatment market research report is one of a series of new reports that provides herpangina treatment market statistics, including herpangina treatment industry global market size, regional shares, competitors with a herpangina treatment market share, detailed herpangina treatment market segments, market trends and opportunities, and any further data you may need to thrive in the herpangina treatment industry. This herpangina treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The herpangina treatment market consists of revenues earned by entities by providing medical services such as symptomatic relief, hydration, soft diet, and oral hygiene. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The herpangina treatment market size is expected to see strong growth in the next few years. It will grow to $2.68 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to emerging viral strains, increasing focus on pediatric health, international health regulations, technological innovations in diagnostics, healthcare access improvements. Major trends in the forecast period include development of topical therapies for oral lesions, integration of telemedicine for diagnosis and consultation, enhanced patient education and awareness programs, collaborations for clinical trials and research, global health preparedness initiatives.
The growth of the herpangina treatment market is anticipated to be driven by an increase in research and development activities. Herpangina is a viral infection that primarily affects children, leading to painful sores or ulcers in the throat and tonsils, typically caused by coxsackievirus and enteroviruses. Treatments for herpangina aim to alleviate symptoms such as blisters, high fever, mouth or throat discomfort, drooling, and loss of appetite. For instance, in April 2024, the Office for National Statistics, a UK-based national statistical agency, reported that the UK government’s net expenditure on research and development increased by 10.5% in 2022, amounting to £15.5 billion ($19.5 billion), compared to £14 billion ($17.7 billion) in 2021. Thus, the rise in research and development activities is contributing to the growth of the herpangina treatment market.
The growth of the herpangina treatment market is also expected to be fueled by the increasing pediatric population. This population segment, encompassing individuals from birth to adolescence or maturity, requires specific attention in herpangina treatment, focusing on symptom management, supportive care, and ensuring proper hydration. The Federal Interagency Forum on Child and Family Statistics reported around 72.5 million children in the United States in 2022, with a projected increase to 78.2 million by 2050. This rise in the pediatric population is a significant driver for the growth of the herpangina treatment market.
The growth of the herpangina treatment market is expected to be propelled by a surge in healthcare expenditure. Healthcare expenditure encompasses all costs related to health services, nutrition activities, family planning, and emergency aid designated for health. An increase in healthcare spending can contribute to the expansion of resources and the availability of trained healthcare professionals for herpangina treatment. According to the Centers for Medicare & Medicaid Services, the National Health Expenditure (NHE) increased by 2.7% to $4.3 trillion in 2021, reaching $12,914 per person. Projected annual increases of 5.1 percent and a 19.6 percent share of GDP in 2030 indicate sustained growth in healthcare expenditure, driving the herpangina treatment market.
The development of treatments for herpangina-related diseases, such as aphthous stomatitis, is a notable trend gaining traction in the herpangina treatment market. Major companies in the market are actively working on therapies to alleviate pain in individuals with recurrent mouth ulcers. For instance, in September 2022, Mucocort, a Sweden-based healthcare company, partnered with Aurena Laboratories AB to create a unique self-absorbing pain relief patch for individuals suffering from recurrent mouth ulcers and aphthous stomatitis, facilitating pain relief and accelerating the natural healing process.
Key players in the herpangina treatment market are focusing on the development of new treatments, including Acetaminophen pain relief products for adults. These products, containing acetaminophen as the active ingredient, aim to relieve pain and reduce fever. In April 2022, Genexa, a US-based pharmaceutical company, introduced 'Genexa Acetaminophen Extra Strength' and 'Acetaminophen PM caplets' for temporary relief from minor aches, discomfort associated with conditions such as the common cold, headaches, backaches, arthritis pain, toothaches, muscular aches, and premenstrual and menstrual cramps. The launch of such products contributes to the diversification and growth of the herpangina treatment market.
Major companies operating in the herpangina treatment market include Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Limited, Pfizer Inc, AstraZeneca, Novartis AG, GlaxoSmithKline Plc, Merck & Co., Inc., AbbVie Inc., Eli Lilly and Company, Bayer AG, Sanofi, Bristol-Myers Squibb Company, Johnson & Johnson, Mucocort, Aurena Laboratories AB, Cipla Inc., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Zydus Cadila, Aurobindo Pharma Ltd., Lupin Limited, Glenmark Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., F. Hoffmann-La Roche AG, Boehringer Ingelheim International GmbH, Sandoz International GmbH, Endo International plc, Mylan N.V., CSL Limited.
North America was the largest region in the global herpangina treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the herpangina treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the herpangina treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Herpangina treatment involves managing the symptoms of the viral illness that commonly affects children, causing painful sores or ulcers on the tonsils and the back of the throat. Treatment focuses on alleviating symptoms and supporting the body's natural healing process, as herpangina is a viral infection that typically resolves on its own without the need for specific antiviral medications.
The main types of herpangina treatment include topical anesthetics, ibuprofen or acetaminophen, and others. Topical anesthetics are a form of local anesthesia applied to the skin's surface or mucous membrane to temporarily numb the affected region. Herpangina is caused by viruses such as coxsackie virus A, coxsackie virus B, enterovirus 71, and echovirus, leading to various symptoms such as high fever, sore throat, blisters or ulcers in the throat and mouth, difficulty swallowing, loss of appetite, headache, neck pain, and swollen lymph glands. These treatments are utilized by various end-users, including hospitals, home care settings, specialty clinics, and others.
The herpangina treatment market research report is one of a series of new reports that provides herpangina treatment market statistics, including herpangina treatment industry global market size, regional shares, competitors with a herpangina treatment market share, detailed herpangina treatment market segments, market trends and opportunities, and any further data you may need to thrive in the herpangina treatment industry. This herpangina treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The herpangina treatment market consists of revenues earned by entities by providing medical services such as symptomatic relief, hydration, soft diet, and oral hygiene. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Herpangina Treatment Market Characteristics3. Herpangina Treatment Market Trends and Strategies4. Herpangina Treatment Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global Herpangina Treatment Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Herpangina Treatment Market34. Recent Developments in the Herpangina Treatment Market
5. Global Herpangina Treatment Growth Analysis and Strategic Analysis Framework
6. Herpangina Treatment Market Segmentation
7. Herpangina Treatment Market Regional and Country Analysis
8. Asia-Pacific Herpangina Treatment Market
9. China Herpangina Treatment Market
10. India Herpangina Treatment Market
11. Japan Herpangina Treatment Market
12. Australia Herpangina Treatment Market
13. Indonesia Herpangina Treatment Market
14. South Korea Herpangina Treatment Market
15. Western Europe Herpangina Treatment Market
16. UK Herpangina Treatment Market
17. Germany Herpangina Treatment Market
18. France Herpangina Treatment Market
19. Italy Herpangina Treatment Market
20. Spain Herpangina Treatment Market
21. Eastern Europe Herpangina Treatment Market
22. Russia Herpangina Treatment Market
23. North America Herpangina Treatment Market
24. USA Herpangina Treatment Market
25. Canada Herpangina Treatment Market
26. South America Herpangina Treatment Market
27. Brazil Herpangina Treatment Market
28. Middle East Herpangina Treatment Market
29. Africa Herpangina Treatment Market
30. Herpangina Treatment Market Competitive Landscape and Company Profiles
31. Herpangina Treatment Market Other Major and Innovative Companies
35. Herpangina Treatment Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Herpangina Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on herpangina treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for herpangina treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The herpangina treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Treatment: Topical Anesthetics; Ibuprofen or Acetaminophen; Other Treatments2) By Virus: Coxsackie Virus a; Coxsackie Virus B; Enterovirus 71; Echovirus
3) By Symptoms: High Fever; Sore Throat; Blisters or Ulcers in the Throat Mouth; Difficulty Swallowing; Loss of Appetite; Neck Pain; Swollen Lymph Glands; and Headache
4) By End User: Hospitals; Homecare; Specialty Clinics; Other End-Users
Subsegments:
1) By Topical Anesthetics: Benzocaine; Lidocaine; Other Anesthetics2) By Ibuprofen or Acetaminophen: Ibuprofen; Acetaminophen; Other Treatments
3) By Antiviral Medications: Corticosteroids; Supportive Care
Key Companies Mentioned: Hoffmann-La Roche Ltd.; Takeda Pharmaceutical Company Limited; Pfizer Inc; AstraZeneca; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Hoffmann-La Roche Ltd.
- Takeda Pharmaceutical Company Limited
- Pfizer Inc
- AstraZeneca
- Novartis AG
- GlaxoSmithKline Plc
- Merck & Co., Inc.
- AbbVie Inc.
- Eli Lilly and Company
- Bayer AG
- Sanofi
- Bristol-Myers Squibb Company
- Johnson & Johnson
- Mucocort
- Aurena Laboratories AB
- Cipla Inc.
- Dr. Reddy’s Laboratories Ltd.
- Teva Pharmaceutical Industries Ltd.
- Zydus Cadila
- Aurobindo Pharma Ltd.
- Lupin Limited
- Glenmark Pharmaceuticals
- Sun Pharmaceutical Industries Ltd.
- Torrent Pharmaceuticals Ltd.
- F. Hoffmann-La Roche AG
- Boehringer Ingelheim International GmbH
- Sandoz International GmbH
- Endo International plc
- Mylan N.V.
- CSL Limited.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | February 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 1.98 Billion |
| Forecasted Market Value ( USD | $ 2.68 Billion |
| Compound Annual Growth Rate | 7.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 30 |
